Lipoproteins and Apolipoproteins in the Prediction of Coronary Artery Disease

  • G. Assmann

Abstract

Atherosclerotic cardiovascular disease is the leading cause of death and also the most frequent cause of early invalidity in most European countries. Clinical conditions such as coronary heart disease (angina pectoris, myocardial infarction, acute cardiac death), cerebrovascular insufficiency (apoplexy), and peripheral arterial occlusive disease (intermittent claudication, gangrene) become manifest following decades of asymptomatic development of atherosclerotic vascular stenosis. In evaluating coronary risk there is a distinction made between primary risk factors (hypercholesterolemia, nicotine abuse, hypertension) and secondary risk factors (diabetes mellitus, obesity, lack of physical activity). The primary risk factors are individually capable of producing clinical complications of atherosclerotic vascular disease. Secondary risk factors, as a general rule, evoke clinical complications only in conjunction with one or more other factors. Individual risk factors should not be viewed as isolated in the course of a disease, since they frequently occur in combination. The incidence of cardiovascular disease increases cumulatively with the presence of multiple risk factors. The concept of a multifactorial basis for the origin of atherosclerotic vascular disease is principally derived from the findings of epidemiological studies. It has been demonstrated quite convincingly in the example of acute cardiac death that risk factors can be identified in the overwhelming majority of cases and that individual risk factors are interrelated.

Keywords

Cholesterol Obesity Filtration Carbohydrate Europe 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    1985) Lowering blood cholesterol to prevent heart disease. Consensus Conference. JAMA 253: 2080–2086Google Scholar
  2. 2.
    Strategy for the prevention of coronary heart disease. A policy statement of the European Atherosclerosis Society. Eur Heart J (in press)Google Scholar
  3. 3.
    Kannel WB, Gordon T (1976) The Framingham study: an epidemiological investigation of cardiac disease: the results of the Framingham study applied to four other US based epidemiologic studies of cardiovascular disease. Publication (NIH) 76–1083, section 31. US Dept of Health, Education and WelfareGoogle Scholar
  4. 4.
    Pooling Project Research Group (1978) Relationship of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormality to incidence of major coronary events: final report of the Pooling Project. J Chronic Dis 31: 201–306CrossRefGoogle Scholar
  5. 5.
    Multiple Risk Factor Intervention Trial Research Group (1982) Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 248: 1465–1477CrossRefGoogle Scholar
  6. 6.
    Stammler J, Wentworth D, Neaton JD (1986) Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the multiple risk factor intervention trial. Am J Med 80 (suppl 2A): 33–36CrossRefGoogle Scholar
  7. 7.
    Lipid Research Clinics Program (1984) The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. JAMA 251: 351–374CrossRefGoogle Scholar
  8. 8.
    Lipid Research Clinics Program (1984) The lipid research clinics coronary primary prevention trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365–374CrossRefGoogle Scholar
  9. 9.
    Assmann G, Schulte H (1986) Procam-trial. Panscientia, Zürich, 1986Google Scholar
  10. 10.
    Assmann G (1982) Lipidstoffwechsel und Atherosklerose. Schattauer, StuttgartGoogle Scholar
  11. 11.
    Assmann G (1983) Apolipoproteinopathien. Klin Wochenschr 61: 169–182PubMedCrossRefGoogle Scholar
  12. 12.
    AssmannG, Lenzen HJ (1985) Apolipoprotein E-Polymorphismen. Hyperlipidämie und Herzinfarktrisiko. Internist 26: 692–700PubMedGoogle Scholar
  13. 13.
    Schriewer H, Nolte W, Robeneck H, Assmann G (1986) Apolipoprotein B determination in the dissolved precipitate obtained after precipitation of LDL with polyvinylsulphate. An alternative method for the determination of LDL apolipoprotein B without using ultracentrifugation. J Clin Chem Clin Biochem 24: 347–352PubMedGoogle Scholar
  14. 14.
    White R, Leppert M, Bishop DT, Backer D, Berkowitz J, Brown C, Callahan P, Holm T, Jerominski L (1985) Construction of linkage maps with DNA markers for human chromosomes. Nature 313: 101–105PubMedCrossRefGoogle Scholar
  15. 15.
    Brown MS, Goldstein JL (1981) Lowering plasma cholesterol by raising LDL receptors. N Engl J Med 305: 505–517CrossRefGoogle Scholar
  16. 16.
    Grundy SM (1984) Recommendations for the treatment of hyperlipidemia in adults. A joint statement for the nutrition committee and the council on arteriosclerosis of the American Heart Association. Arteriosclerosis 4: 445–468Google Scholar
  17. 17.
    Havel RJ, Kane JP (1982) Therapy of hyperlipidemic state. Annu Rev Med 33: 417–433PubMedCrossRefGoogle Scholar
  18. 18.
    Heel RC, Brogden RN, Speight TM, Avery GS (1978) Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolemia. Drugs 15: 409–428PubMedCrossRefGoogle Scholar
  19. 19.
    Illingworth DR, Sexton GJ (1984) Hypercholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest 74: 1972–1978PubMedCrossRefGoogle Scholar
  20. 20.
    Levy RI (1985) Primary prevention of coronary heart disease by lowering lipids: results and implications. Am Heart J 110: 1116–1122PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • G. Assmann

There are no affiliations available

Personalised recommendations